Showing posts with label Prescription. Show all posts
Showing posts with label Prescription. Show all posts

Sunday, August 20, 2017

Sleep Deprivation Through Pain Some Non Prescription Supplement Ideas


Today's post from webcache.googleusercontent.com (see link below) comes from the New York Buyers Club, which is a well-known and established supplement company. However, it is also known for its very useful non-biased medical information and can be very useful if you are wondering about the pros and cons of taking supplements. This article talks specifically about sleep deprivation and depression being a vicious circle and suggest which non-prescription supplements may help. You may wonder what this has to do with neuropathy but the fact is that very many neuropathy patients have trouble getting a good nights rest. Their sleep is often disturbed by neuropathic symptoms flaring up at night. This in turn can lead to depression (not a big stretch if you have neuropathy and can't sleep). You may find some of the information and suggestions provided here to be useful in your own situation. Worth a read.

New research on depression, and a new look at supplements for mood and sleep disorders 
Posted  by jarebe
This article from the Spring 2014 edition of SUPPLEMENT: Newsletter of the New York Buyers Club

At the end of 2013, there was much buzz about new studies showing that curing insomnia in people with depression might double the chance of a complete recovery from depression. The studies, financed by the National Institute of Mental Health, were welcomed as the most significant advance in treating depression since the introduction of the “selective serotonin re-uptake inhibitor” (SSRI), Prozac, twenty-five years ago. In effect, the new research findings turn conventional wisdom on its head, since they suggest that insomnia can be a main cause of depression, rather than just a symptom or a side effect, as previously assumed. If you can successfully treat a depressed person’s insomnia, according to the new view, you eliminate one of the main factors causing the depressed state.

New research findings turn conventional wisdom on its head
suggesting that insomnia can be a main cause of depression
rather than just a symptom or a side effect as previously assumed

As we followed reports on this breakthrough research on insomnia and depression, we were especially encouraged to read comments like the one from Washington DC psychiatrist James Gordon, who has advocated an integrative approach to treating depression. Here’s his letter to The New York Times:

I welcome a new report’s finding that cognitive behavioral therapy is improving the outcome for depressed people with significant insomnia (“Sleep Therapy Seen as an Aid for Depression,” front page, Nov. 19).

It reminds us that changes in attitude and perspective, and a therapeutic relationship, can right biological imbalances — like disordered sleep — and significantly enhance the lives of troubled people. The study also puts the therapeutic role of antidepressant medication in perspective: the depressed participants who received behavioral therapy did equally well whether or not they were taking the drugs.

I hope that these results will encourage the National Institute of Mental Health, researchers, clinicians and all of us to expand our horizons.

There are a number of other nonpharmacological therapies, including meditation, physical exercise, dietary change and nutritional supplementation, acupuncture and group support, that show promise for improving clinical depression and enhancing brain function.

At NYBC we have long believed that non-prescription therapies, such as supplements, are valuable alternatives for treating mood disorders and sleep disorders When the Centers for Disease Control surveyed use of antidepressant drugs in 2008, it found that one in 10 Americans was taking an antidepressant, and many had taken these drugs for years. Over a period of ten years, antidepressant use in the U.S. had shot up by 400%! So the question arises: how much of this spectacular increase represented real gains in treatment, and how much was over-prescribing? As Dr. Gordon mentions in his letter above, in some cases behavioral therapy for depression has worked just as well whether people were taking antidepressants or not—hardly a strong argument for the value of the prescription drugs.

A well-publicized 2008 report in the New England Journal of Medicine
found that pharmaceutical companies had consistently reported
only the most favorable trial outcomes for their popular antidepressants

A well-publicized 2008 report in the New England Journal of Medicine found that pharmaceutical companies had consistently reported only the most favorable trial outcomes for their popular antidepressants, passing over evidence that suggested a more limited effectiveness. Furthermore, as with many drugs, especially those used over a long period, antidepressants have side effects. Higher bone fracture risk and multiple cardiovascular risks have been identified; sexual side effects are common with antidepressants in both men and women; and withdrawal symptoms for those tapering off antidepressants include a long list of problems, such as panic attacks, insomnia, poor concentration and impaired memory.

Turning to the alternatives, we describe below supplements that NYBC has highlighted over the years for sleep and mood disorders. Note cautions about their use, but also note that some of these products may actually carry added benefits, rather than unwanted side effects.

1. Melatonin is a hormone occurring naturally in the body, but some people who have trouble sleeping have low melatonin levels. Melatonin has been used for jet lag, for adjusting sleep-wake cycles for people doing shift work on varying schedules, and for insomnia, including insomnia due to high blood pressure medications called beta-blockers. It is also used as a sleep aid when discontinuing benzodiazepines (Klonopin, Xanax, etc.) and to reduce side effects when quitting smoking.

2. Fish Oil
. Epidemiologists have noted that populations that eat fish regularly have low rates of depression. And research has found that omega-3 fatty acids in fish oil supplements can be of benefit in treating depression and bipolar disorder. Fish oil can also be taken with other anti-depressants as an adjunct therapy. Doses found effective in treating depression are quite high, 3 to 9 grams per day, so be aware of potential problems related to the supplement’s blood-thinning properties. Added benefit: fish oil can help manage cholesterol, and supports cardiovascular health.

3. Deficiencies in the B Vitamins, especially B12 and folate, can result in neurologic symptoms — for example, numbness, tingling and loss of dexterity — and the deterioration of mental function, which causes symptoms such as memory loss, confusion, disorientation, depression, irrational anger and paranoia. A number of studies have shown that vitamin B12 is deficient in a large percentage of people with HIV, and the deficiency can begin early in the disease. Supplementing with a B complex protects against deficiency and supports cognitive health and mental function.

4. Vitamin D deficiency has also been linked to depressed states. Lack of the “sunshine vitamin” may be especially associated with Seasonal Affective Disorder (SAD), the “winter blues.” Vitamin D also supports bone health, and may protect against colds and flus.

5. Theanine, an amino acid found in green tea, acts as a relaxing agent by increasing levels of certain neurotransmitters (=brain chemicals that shape your mood), including serotonin, dopamine, and GABA (gamma amino butyric acid). Human studies have been limited to date, but one small study showed that theanine decreases stress responses such as elevated heart rate. Another investigation compared theanine’s calming effect to that of a standard anti-anxiety prescription drug, and found that theanine performed somewhat better. Note that NYBC stocks Theanine Serene (Source Naturals), a combination supplement that includes theanine and GABA.

6. Probiotics. Very recent research has looked into the communication between the digestive system and the brain, with a goal of understanding how gut health may influence chronic conditions, including mood disorders like depression and anxiety. For example, it has been shown that certain probiotics promote production of the calming, anti-stress neurotransmitter GABA in the body, pointing to a direct influence of probiotics on mood. Other potential links between the gastrointestinal system’s microorganisms and brain function are currently being explored.

7. L-Tryptophan and 5-HTP (5-hydroxy L-tryptophan). These closely related supplements are converted in the body to serotonin and to melatonin. (Take L-tryptophan with carbohydrates to make it effective.) Their use as antidepressants has been studied, and they have also been found to aid sleep and suppress appetite. (To minimize appetite suppression, take the supplement an hour before bedtime.) Although L-Tryptophan and 5-HTP are close relatives, people may respond somewhat differently to them, so it may be worthwhile to try the other if the first doesn’t produce an effect An added benefit: 5-HTP may also decrease symptoms of fibromyalgia and migraine headaches.

8. In research funded by the National Institute of Mental Health, DHEA (dehydroepiandrosterone) was found to be an effective therapy for mild-to-moderate or severe midlife depression, on par with some prescription drugs. Moreover, the research showed that taking DHEA promoted both a significant lifting of depressive symptoms and an improvement in sexual functioning. Note that dosing recommendations vary for men versus women, and DHEA is not recommended for those diagnosed with prostate conditions or cancer.

9. SAMe (S-adenosyl-l-methionine) is produced naturally in the body from the amino acid methionine. Supplementing with SAMe increases concentrations of the neurotransmitters serotonin and dopamine. Several studies show SAMe having an antidepressant effect comparable to that of some prescription drugs. SAMe should be avoided in people with bipolar disorder, and should be used cautiously with other antidepressants, because the combination may push serotonin levels too high. Taking a B-complex vitamin while using SAMe can counter build-up of homocysteine, which has been linked to heart disease SAMe may also support joint health and liver function. Caution: the National Center for Complementary and Alternative Medicine has posted a warning that SAMe may increase likelihood of pneumocystis infection in immune-compromised people. Note: see also Trimethylglycine (TMG), which includes the raw materials that the body uses to manufacture SAMe. TMG is much less expensive than SAMe.

10. St. John’s Wort
is a widely used herb with clinically demonstrated (multiple, well-controlled studies, mostly in Europe) anti-depressant effects for mild to moderate depression – generally without the side effects of prescription antidepressants. High doses of the herb may cause a sensitivity to light (phototoxicity), so avoid direct sunlight or sunbathing while using. Do not take St. John’s Wort with 5-HTP, serotonin re-uptake inhibitors (like Prozac), or with protease inhibitors, as it may affect beneficial liver enzymes. St. John’s Wort may also have activity against Epstein-Barr and herpes infections. (St John's Wort should not be used in conjunction with HIV medications Ed:)

11. Finally, we’ll mention another combination supplement that NYBC has stocked: GABA Soothe (Jarrow). The GABA in this supplement is the neurotransmitter that promotes calmness coupled with mental focus. Also included is theanine (see above for a description of its anti-anxiety effects) and an extract of ashwagandha, an herb which has long been used in the Ayurvedic tradition of India to reduce fatigue and tension associated with stress.

http://webcache.googleusercontent.com/search?q=cache:g1tVAtpNWmIJ:nybc.wordpress.com/+&cd=17&hl=en&ct=clnk&gl=nl&client=firefox-a

Wednesday, August 16, 2017

Neuropathy Caused By Prescription Drugs Vid


Today's video post from beatingneuropathy.tv (see link below) sees Dr John Hayes talk about a subject that's all over the internet at the moment and that's neuropathy caused by some of the drugs used to treat other conditions (statins and certain types of antibiotics for instance). It is essential to ask your doctor if the drugs he or she prescribes, are likely to cause neuropathy and if so, ask for alternatives. If you're still not happy, Google the name of the drug and neuropathy and see if there are potential problems.



Episode 36 – Drug-Induced Neuropathy
Wednesday, December 4th, 2013
Posted by John Hayes Jr

Drug induced neuropathy is now more common than ever. In this video, Dr. Hayes discusses the most common drugs that are associated with the eventual development of neuropathy. Watch carefully, listen and learn. Be especially careful if you take or have taken in the past statins, antihypertensives, and modern classes of antibiotics.



http://beatingneuropathy.tv/2013/12/episode-36-drug-induced-neuropathy/

Tuesday, August 15, 2017

Responsible Opioid Prescription For Neuropathy Pain


Today's post from updates.pain-topics.org (see link below) talks about something that many neuropathy patients have issues with and that's the effects of long-term opioid use. Unfortunately, for many people with neuropathy, the pain is just too great to be able to function normally. All of the usual medication options have been tried and have failed and the only possible pain control left is opioids. The problem is their addictiveness and the fact that some of the general population have taken to using them recreationally. Whatever the outcome of various debates around this subject; if you take opioids you need to know that someone qualified is monitoring your progress so that addiction problems can be minimised but for many people, not taking them is not an option.


Opioids on Trial, But Where’s the Evidence?
Wednesday, August 8, 2012

A recent Citizen Petition to the United States Food and Drug Administration (FDA) by Physicians for Responsible Opioid Prescribing, or PROP, requests labeling changes for all opioid analgesics when it comes to their prescription for noncancer pain. The changes would limit the dose, impose time limits, and restrict opioid use for only severe pain.

The Petition raises some important questions about the safety and efficacy of opioid analgesics as they are currently FDA-approved and prescribed. And, the urgency of an investigation was heightened by the fact that a Congressional committee has joined the petitioners in demanding action from the FDA. But, a critical question is whether there is sufficient evidence of reasonable quality for the FDA to act on the Petition at this time.

A Crisis of Confidence in Evidence
At every turn these days, opioid analgesics seem to be on trial, whether in the court of public opinion fueled by mass media, in the U.S. Congress and state legislatures, in various government agencies, and among select groups of healthcare professionals. Yet, what may be most at stake here is a crisis of confidence in scientific methods of inquiry and the reliance on valid research evidence as proof when it comes to making judgments that guide clinical practice in pain management.

Since our inception in late 2005, the mission of Pain Treatment Topics has been to focus on principles of evidence-based pain management. In Part 11 of our ongoing series, “Making Sense of Pain Research”, we examined several questions: What qualifies as evidence? What are the requirements of evidence as proof? How much proof is necessary for reaching valid and just clinical decisions?

We reminded readers, “Just as juries need good evidence to reach prudent verdicts, healthcare providers need good evidence as a guide for better decision-making in treating patients with pain.” However, due to the nature of scientific inquiry and research methods, absolute certainty is an illusion and research outcomes must be used circumspectly and wisely for reaching judicious conclusions affecting patients’ health and well-being.

We say all of this because, as much as anything, the PROP Petition  raises questions about how pain research evidence could and should be interpreted and used for influencing decision-making and change. And, it also raises questions regarding the quality, quantity, relevance, and validity of evidence necessary for establishing an acceptable level of proof in pain management.

In previous UPDATES, we have dissected, discussed, and/or challenged much of the evidence that is used in the PROP Petition to support their requested changes to opioid-product labeling. This and additional evidence also is discussed in a recent guest author UPDATE  by Bob Twillman, PhD, FAPM, and further opinions debating claims of the Petition are offered elsewhere by clinical pharmacy specialist, Jeffrey Fudin, RPh, PharmD, DAAPM, FCCP

In short, there does not appear to be a body of good, clear, and convincing evidence at this time to support the requests in the Petition, let alone any evidence beyond reasonable doubt for passing judgment. However, this is not to say that the petitioners’ assertions are frivolous or unworthy of further investigation and discussion.
In fact, the FDA has posted the Petition at the U.S. government site — www.Regulations.gov — and is accepting public commentary. The URL link is: http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0001
Document Name: Physicians for Responsible Opioid Prescribing - Citizen Petition
Document ID: FDA-2012-P-0818-0001
Docket ID: FDA-2012-P-0818
We should note that commenting is not limited to Americans, and persons from all parts of the world may have much at stake here. Changes to opioid labeling and prescribing in the U.S. may inspire other countries to re-examine how these medications should best be prescribed in their own populations. We would encourage any and all persons with something to say on this matter, pro or con, to submit a comment.

Here is the text of the public comment letter that we submitted to the FDA on August 6, 2012; Tracking ID# 810c2f4b….
+++++++++++++++++++++++++++++++++++++++++++++++++++++++
TO: FDA Docket ID: FDA-2012-P-0818 at www.Regulations.gov
RE: Physicians for Responsible Opioid Prescribing - Citizen Petition
FR: Stewart B. Leavitt, MA, PhD, on behalf of
Pain Treatment Topics
On July 25, 2012, Physicians for Responsible Opioid Prescribing (PROP) and allied signatories submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting certain changes to opioid analgesic labeling. These would limit opioid dosing, impose time limits, and restrict opioid use in noncancer conditions to only severe pain.

The Petition appears to be most concerned with opioid analgesia for chronic noncancer pain, and excludes cancer-related pain, but there is some confusion as to whether the label changes would apply also to acute pain. In any event, it seems that the broad and implicit hypothesis underlying the Petition might be stated as this:
Compared with opioid analgesic prescribing practices following indications on current product labeling, patients would be afforded superior effectiveness and safety if opioids were restricted to a dose of ≤100 mg/day of morphine or its equivalent for no more than 90 continuous days and only for severe pain in the case of noncancer conditions.
If this hypothesis is true, countless patients are possibly being mistreated or harmed by current prescribing practices, and it would be important to know if any or all of the Petition’s recommendations should be adopted. As it presently stands, however, there are some serious concerns regarding acceptance of the Petition and its implicit hypothesis:
  • The hypothesis has not been directly tested by adequate, prospective clinical research trials of any quality or sufficient quantity.
  • Current best evidence submitted by the petitioners under their “Statements of Scientific Basis for Petition” has been challenged in terms of its relevance, adequacy, and/or validity [Twillman 2012, ref below].
  • Limited clinical evidence presented at a recent FDA-sponsored Workshop last May, 2012, to assess analgesia for chronic pain was largely of lower quality — observational or epidemiological — and generally equivocal or inconclusive regarding the absolute benefits vs risks of long-term opioid therapy at any dose for various types of pain conditions [FDA 2012].
Therefore, the Petition proposes a hypothesis that raises important questions but, in itself, is untested and unproven. And, it seems apparent that, at this time, changing opioid-product labeling in accordance with the Petition’s requests could be tantamount to enrolling millions of persons with pain — unknowingly and non-consenting — as participants in a clinical experiment to test an unfounded medical theory.

Certainly, the clinical, scientific, ethical, and legal implications of this are daunting, and memory of egregiously cruel human experiments in history would seem to preclude the labeling change at present. Unintended consequences of the label change could possibly be significantly adverse and harsh.

Still, in the court of scientific inquiry there seems sufficient evidence for reasonable suspicion that some, if not all, of the Petition’s perspectives could merit further investigation. Government research-oriented agencies might be encouraged to examine these issues further and to fund the necessary well-designed clinical investigations.
First, however, it would be necessary to operationally define what is specifically meant in the Petition by such terms as: safety, effectiveness, noncancer, and severe pain. And, to better justify for testing the assignation of ≤100 mg/day morphine or equivalent and 90 days duration as threshold points.

Surely, opioid analgesics are not the only or best solution for all types of pain, whether acute or chronic, cancer or noncancer, and in all patients. Ultimately, the goal is to afford patients the best possible pain management, and to identify those patients who might benefit most from opioid analgesia at any dose and/or for any length of time.

References:
> Twillman R. Group Petitions FDA to Change Opioid Label. Pain-Topics UPDATES. 2012(Aug 2); available online at:
http://updates.pain-topics.org/2012/08/group-petitions-fda-to-change-opioid.html
> FDA (U.S. Food and Drug Administration). Assessment of Analgesic Treatment of Chronic Pain: A Scientific Workshop. 2012(May); available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM309444.pdf

+++++++++++++++++++++++++++++++++++++++++++++++++++++++
Our purpose in commenting was not to challenge particular research referenced in the Petition or the specifically requested changes; rather, to address issues of scientific method and the uses of evidence as proof. Quite simply, a new clinical hypothesis requires some basis in science or prior evidence to justify testing — which might be met by the limited evidence cited in the Petition — but the hypothesis itself should not be not put into practice until it has been tested and proven valid. Essentially, if opioid labeling were changed at this time in accordance with the Petition it would be “putting the cart before the horse” from an evidence-based medicine perspective.
In his recent guest author Pain-Topics UPDATE, Dr. Twillman, PhD, FAPM, did a thorough job of discussing and questioning the evidence base behind the Petition. In fair balance, immediately after we posted the Twillman UPDATE, we alerted Andrew Kolodny, MD, of the article; he is president of PROP and a principal signer of the Petition. We extended to Dr. Kolodny, and any fellow cosigners of the Petition, an open invitation to submit for publication a rebuttal UPDATE article commenting on Twillman’s critique and/or further presenting their own perspectives. [ADDENDUM: Dr. Kolodny did respond to us later today:

Congress Embraces the Petition
US CongressOn July 26, 2012 — just one day after the Petition was filed with the FDA — Congresswoman Mary Bono Mack and 5 fellow members of the Congressional Caucus on Prescription Drug Abuse sent a public letter  to Margaret Hamburg, MD, FDA Commissioner, essentially endorsing the Petition and embracing all of its recommended labeling changes. The letter concludes:
“We believe that if a labeling change were made to opioid analgesics to reflect the uncertainty and lack of evidence surrounding safety and effectiveness of these drugs for treatment of chronic non-cancer pain, physicians would think twice before prescribing these highly addictive narcotics for ‘moderate’ pain such as a toothache or sore knee. While those who seek treatment for cancer pain and other diseases that cause “severe” pain would not be affected, the number of individuals prescribed opiate painkillers without evidence of the long-term safety and effectiveness may decrease and limit those susceptible to developing opioid dependence.”
To our knowledge, none of these elected officials has extensive medical training or expertise in the assessment of research evidence. Their statement reflects some bias in the use of emotion-laden terms — eg, “highly addictive narcotics” and “painkillers” [discussed previously in an UPDATE  — and, they appear to advocate against even the short-term use of opioids for acute pain, such as a toothache, which is an unclear aspect of the Petition. The Caucus members also seem to have accepted the false argument of the petition, that a lack of evidence is, in itself, acceptable evidence for advocating against the long-term effectiveness and safety of opioids for noncancer pain.
Still, this letter commands the attention of the FDA, since it ends with, “For these reasons, we request an expedited review of the Citizen Petition submitted to FDA, and look forward to a timely response.”

What Happens Now?
FDAIn fairness, the letter from Congresswoman Mack and colleagues was merely instructing the FDA to look into the matter and report back. The FDA already held a Workshop last May exploring analgesia for chronic pain, but this letter probably motivated the agency to accept and post the Petition at the government regulations website on July 30, 2012, for further public comment. Again, that site can be accessed .
We have from time to time been critical of the FDA; yet, we know that the agency performs a vital function and is staffed with well-trained and dedicated physicians and scientists. They understand the ins and outs of pain research and are unlikely to be swayed by low-quality, biased, or inadequate evidence.
In our opinion, there is more at stake here than the fate of opioid analgesics prescribed for chronic noncancer pain. Conflicts of dogma versus science are at the core of many practices in the pain management field; yet, low-quality evidence and fallacies of logical thinking sometimes appear to be winning the battle.
Furthermore, some of the nuances and ramifications of the petitioned label change must be considered:
  • Some have argued that changing the label would stop pharmaceutical companies from promoting opioids for uses beyond the new, more limited indications, but, if deemed necessary, practitioners could still prescribe the medications off-label at any dose and for any duration of time in noncancer pain.

    However, off-label applications of medications are usually discouraged and can be risky; prescribers know that they could face regulatory scrutiny or liability issues if something goes wrong and they have not followed FDA-approved indications on labeling. The Congressional Caucus members are aware of this when they state, “…physicians would think twice before prescribing these highly addictive narcotics.”      
  • This further raises the question of addiction to opioid analgesics among legitimate patients with pain. Evidence regarding this is discussed by Twillman in his UPDATE, and this still appears to be an unresolved issue needing further definition, investigation, and clarification. Yet, the Caucus members seem to accept the notion that restricting opioid prescribing, “may decrease and limit those susceptible to developing opioid dependence.” By dependence, we presume they mean “addiction” here, rather than the physiological dependence on opioids that naturally develops in many cases; although, whether or not they fully understand the distinctions seems unknown.      
  • In reaction to the Petition, some professionals have questioned whether public and private healthcare insurance plans would continue to pay for opioid prescriptions that did not adhere to new restrictions indicated on labeling. If not, patients with chronic pain would need to personally absorb the financial burden associated with off-label opioid prescribing, which in many or most cases could preclude or curtail their ongoing access to these medications. Any answers to insurance coverage questions at this time would be speculative.     
  • Most worrying are questions not even raised and addressed in the Petition or by Congressional Caucus members. What should take the place of opioid analgesics for chronic noncancer pain? What are the better, safer, tried and proven therapies?
There are no easy answers to questions and evidentiary dilemmas posed by the Petition. Our own recommendation is that, if the Petition is to be serously considered and judged, there first must be an objectively thorough review and critical assessment of all relevant evidence regarding this issue — pro and con. And, hopefully, these inquiries and further dialogue will be fair-balanced and steered by science — embracing principles of evidence-based medicine — rather than driven by dogma and demagoguery.

http://updates.pain-topics.org/2012/08/opioids-on-trial-but-wheres-evidence.html

Sunday, July 16, 2017

Inconsistent Opioid Prescription Confusing For Patients


Today's post from the ever consistent pain-topics.org (see link below) looks once again at the problems surrounding opioids, especially in North America. More and more people who are genuinely in need of opioids as the only way of controlling their pain, are finding their supplies cut off because of severe legislation meant to tackle drug abuse and crime. Somehow the legislators haven't found a way to separate the genuine need from the addiction which feeds criminality, so are using a 'cover all' approach which means thousands of people are being unfairly treated. It's a growing problem as more and more doctors and pharmacies are reluctant to issue opioid prescriptions for fear of running foul of the law.

Influences on Opioid Rx for Chronic Pain Studied

Posted by SB. Leavitt, MA, PhD Friday, August 9, 2013

Opioids are still among the most commonly prescribed analgesics for treating moderate-to-severe pain. Overall, their use has been increasing even though prescribers are becoming concerned about adverse effects, misuse and abuse, morbidity and mortality, and scrutiny by federal and state regulatory agencies. Two recently published surveys of healthcare providers show that some have stopped prescribing opioids entirely for chronic noncancer pain while others, having more experience with opioids and positive attitudes, continue to prescribe these essential drugs without reluctance.

Opioid Prescribing Changes in Washington State Surveyed

In the first study, researchers in Washington State conducted a survey of primary care physicians and advanced registered nurse practitioners (ARNPs) in the state to understand changes in practice patterns regarding the prescription of opioids for treating chronic noncancer pain (CNCP) [Franklin et al. 2013]. Data were gathered via a web-based anonymous survey conducted during March-August 2011. Participants included a convenience sample of healthcare providers in Washington representing diverse geographic regions and healthcare organizations.

Writing in the July/August 2013 edition of the Journal of the American Board of Family Medicine the researchers report that 623 of 856 provider respondents (73%) claimed to treat patients with CNCP, and these practitioners served as the analysis sample. Most of these providers (72%) reported concerns about opioid overdose, addiction, dependence, or diversion, while only 25% indicated concern about regulatory scrutiny.

Only a small proportion of providers overall (3.3%) said that they had stopped prescribing opioids for CNCP, but twice as many ARNPs (5.8%) as physicians —MDs or osteopaths — (2.1%) reported opioid discontinuation. At the same time, a greater proportion of physicians (71%) than ARNPs (40%) reported familiarity with the Washington State opioid dosing guidelines then in existence.

Of interest, physicians in a large health plan serving 400,000 members in Washington (Group Health), which has substantial infrastructure support, reported less concern about problems with opioids compared with providers in other settings. For example, no providers with Group Health had stopped prescribing opioids; whereas, of providers in Spokane (the largest city in Eastern Washington), 45% reported very low capacity to access pain specialty consultation or other support and consequently were less frequent prescribers of opioids at any dose.

The vast majority of providers reported a need for more efficient, innovative means of support and education related to treating patients with CNCP. Overall, prescribers in Washington reported ongoing concerns regarding opioid use for CNCP, but those affiliated with a large healthcare organization and having access to pain consultation were less likely to report being concerned about opioid-related problems or to have discontinued prescribing opioids.

Opioid Rx Rates Influenced by Prescribers’ Attitudes and Experience

The second study was industry-sponsored (Janssen Scientific Affairs) and published in the June 2013 edition of the Journal of Pain. Researchers found that practitioners’ attitudes about pain drugs closely affect how often they prescribe opioids for CNCP (chronic noncancer pain) [Wilson et al. 2013]. As might be expected, negative physician attitudes about opioid medications appear to be associated with lower rates of prescribing and more favorable attitudes are linked with higher prescribing levels.

This study, conducted by University of Washington researchers and collaborators, used a 38-item questionnaire to assess present-day attitudes reflecting impediments and concerns regarding opioid prescribing, perceived efficacy of opioids, medical education, and benefits of tamper resistant formulations (TRFs). Of 1,535 physicians assessed in the final survey more than 70% reported using opioids in fewer than 30% of their patients with CNCP.

Of particular interest, those physicians who treated higher volumes of patients experiencing CNCP were more likely to prescribe opioids and said that they were less concerned with impediments surrounding opioids, were not worried about or avoidant of prescribing Schedule II vs. Schedule III drugs, believed in the benefits of TRFs, and thought that they were adequately trained to treat chronic pain.

According to the researchers, these results are consistent with other studies showing that physician uneasiness with prescribing long-term opioids for chronic pain is linked with inexperience in using the medications. There were no differences evident in overall physician attitudes about opioids in various areas of the country; however, the researchers noted that orthopedists expressed the most negative views of opioids, showed the lowest level of confidence in opioid efficacy, and had the highest average levels of concern about opioid addiction, tolerance, and dependence.

COMMENTARY: The survey by Franklin and colleagues [2013] may be conveying false perceptions that are contrary to current realities in Washington State. For one thing, the survey depicts a point in time that may no longer be relevant; that is, data collection was concluded in August 2011, but the study was not even submitted for publication until 14 months later in October 2012 and was just recently published in summer 2013.

Meanwhile, aggressive new laws (as opposed to mere guideline recommendations) for the management of CNCP — intended to curb opioid-related problems in Washington State — had gone into effect in January 2012 [see discussion in UPDATE here]. In advance of enactment of the new rules, some reports noted that as many as 70% of community health clinics in the state had stopped treating patients with chronic pain, and most of those that still did treat such patients would not provide opioid analgesia. Therefore, the out-of-date survey by Franklin et al. may grossly understate the extent to which prescribing practices negatively changed in the state.

Furthermore, the survey by Franklin et al. used a convenience sample, with a low response rate, that was slanted toward physicians in the large and highly supportive Group Health system. These respondents were less intimidated by opioid-dosing guidelines than other prescribers in the state — eg, none in Group Health had completely discontinued opioid prescribing — but this may or may not hold true today, more than 2 years after the survey. Meanwhile, all indications are that problems have grown worse rather than better for patients who might benefit from opioid therapy for chronic pain in Washington State; and, there have been other unintended consequences.

For example, according to newly reported research, heroin use is on the rise in Washington State and the upsurge can be traced to the new laws that made it more difficult to obtain prescriptions for opioid analgesics [see June 12, 2013 U.S. News & World Report article here]. Implementation of the new opioid-Rx laws decreased the numbers of people abusing opioid analgesics, but also increased the demand for heroin in the state.

As noted by study author Caleb Banta-Green of the University of Washington, “We were either progressive or regressive with that aggressive effort to reign in opiate prescribing before a lot of the country.” He conceded, “It shows if you enact these laws, you get some of the intended effects — high school sophomores have significantly decreased the rate at which they’re abusing prescription opiates — but people are also diverted to heroin.” This increase in heroin use is not new, and has been occurring nationwide as regulators and legislators have tried unsuccessfully to grapple with opioid-related problems [see most recent UPDATE on this topic here].

The second study noted above, by Wilson et al. 2013, appears to confirm general assumptions that prescriber attitudes toward opioid prescribing are favorably influenced by their education and experiences in using the drugs and by treating more patients with CNCP. It seems to be a case of familiarity with opioids and their effectiveness builds comfort that overcomes other concerns.

Among the various speciality groups surveyed, orthopedists were most troubled by impediments/concerns relating to long-term opioid use and had the least confidence in opioid efficacy, whereas pain medicine specialists and physical medicine and rehabilitation specialists were the most confident in opioid use and effectiveness. However, it must be considered that orthopedists most often treat patients with acute pain conditions and have less familiarity with CNCP.

The survey revealed additional factors that may influence attitudes and prescribing practices; although, the significance and universal applicability of these should be circumspectly considered. For example, male physicians on average believed more strongly in the efficacy of opioids for CNCP than females; physicians less than 45 years of age were slightly less confident in prescribing opioids compared with those between 45 and 60 years; and physicians with less than 10% of their patients having chronic pain believed significantly less in opioid efficacy compared with those having greater percentages of patients with CNCP.

Taken together, the two studies appear to emphasize practitioners’ needs for evidence-based guidance, tools and resources, as well as ongoing education regarding benefits and risks of opioid analgesics for CNCP. As might be expected with any medical therapy, practitioner confidence and expertise increase as opioid prescribing experience accumulates. This further suggests that generalizations about successes or failures of opioids for treating CNCP conditions should take into account differential qualifications, attitudes, and beliefs of the prescribing healthcare providers.

REFERENCES: > Franklin GM, Fulton-Kehoe D, Turner JA, et al. Changes in Opioid Prescribing for Chronic Pain in Washington State. J Am Board Fam Med. 2013;26:394–400 [access here].
> Wilson HD, Dansie EJ, Kim MS, et al. Clinicians' Attitudes and Beliefs About Opioids Survey (CAOS): Instrument Development and Results of a National Physician Survey. J Pain. 2013(Jun);14(6):613-627 [abstract].

http://updates.pain-topics.org/2013/08/influences-on-opioid-rx-for-chronic.html

Wednesday, July 12, 2017

Prescription Drug Misuse Declining Or Not


Today's post from pain-topics.org (see link below) follows on from yesterday's post in that it looks at the results of prescription drug availability and abuse. It seems, according to the report, that non-medical drug abuse has and is falling in the USA while prescription drug abuse is clearly rising. The report highlights medical drug abuse as being a big problem for now and the future but as Dr Leavitt's commentary below suggests, it may not be as cut and dried as it seems. Either way, as neuropathy patients who are on opioid and opium family drugs well know, the potential for addiction is always there and patients need to be carefully and regularly monitored by their doctors, to try to minimize the risk.



Rx Pain Reliever Misuse Declining?
Posted by SB. Leavitt, MA, PhD: Thursday, January 10, 2013

A new United States government report shows that prescription drug misuse decreased in 10 states between 2009 and 2011, and did not increase in any other states during that time. Yet, the government seems unimpressed by these results, and there could be biases in the reporting that are distorting the evidence to make the problems loom larger than reality as well as overlooking underlying causes.

The report issued by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) on January 8, 2013 [available here] notes that 22 million people used prescription pain-relieving drugs for “nonmedical purposes” since 2002. And, such Rx-drug misuse is just behind marijuana as the country’s most widespread drug problem, according to SAMHSA.

At the same time, however, the report states that comparisons of combined 2009-2010 data with combined 2010-2011 data show that past year nonmedical use of prescription pain relievers among persons aged 12 or older decreased in 10 states (Kentucky, Louisiana, Massachusetts, Mississippi, New Hampshire, New York, Ohio, Oklahoma, Rhode Island, and West Virginia), and leveled-off during that timeframe in all other states on average.

Iowa had the lowest rate of nonmedical prescription drug use, at 3.6%, while Oregon had the highest rate — 6.4%. Seven of the 10 states with the highest levels of prescription analgesic misuse were in the West: ie, Washington, Oregon, Nevada, New Mexico, Idaho, Colorado, and Arizona. Two other high ranking states were in the South (Arkansas and Delaware), and one was in the Midwest (Indiana).

The national rate for the overall U.S. population declined between 2009-2010 and 2010-2011 — from 4.9% to 4.6%. The rates also decreased nationally during those time periods among persons aged 12 to 25, but remained unchanged overall among persons aged 26 or older. This older group already had analgesic misuse rates significantly lower than teenagers and young adults, but even among older persons there were declines in many states.

Data for the report were from the National Survey on Drug Use and Health (NSDUH), which asks persons aged 12 or older questions related to their nonmedical use of prescription pain relievers during the past year. Such “nonmedical use” is defined as (a) use of the analgesics without a prescription, or (b) use that occurred simply for the experience or feeling the drug caused; over-the-counter (OTC) drug use and legitimate use of prescription analgesics are not included.

In a news release [here], Pamela S. Hyde, SAMHSA Administrator, stated…

“Addressing prescription drug misuse remains a top public health priority, as we’ve seen inconsistent progress in addressing the issue across the states. Data from this report helps us better understand geographic variations in use, and should help with the development of more targeted and effective prevention and treatment programs. The key is educating the public on the serious health risks involved, and ensuring that we are providing the necessary treatment to those who need it.”

COMMENTARY: This report is significant news, since nonmedical use has declined even as the rate of analgesic prescribing overall has been increasing. Yet, the government often appears to emphasize the negative side of such data in continuing to portray an “epidemic” of prescription drug misuse, rather than lauding the remarkable progress that has been made.

Importantly, definition of the problem may be contributing to misperceptions that inflate the data. “Nonmedical use” of prescription analgesics is conflated with abuse, and includes using the drugs either for recreational purposes to get “high”OR using the drugs as intended for pain, but without appropriate authorization — a form of “medical misuse.”

In other words, someone who once “borrowed” a prescription pain reliever from a relative or friend for a toothache, and answered honestly on the NSDUH survey, would be categorized as a nonmedical user (abuser). This is the same category as someone who stole prescription pain pills from their parents’ medicine cabinet to get high at a party. Yet, the motivations are strikingly different, even though both uses could be quite hazardous, and solutions to the respective problems also would be very different.

For example, some time ago in an UPDATE article [here] we reported on a large survey of high school seniors that found 12.3% of them used opioid analgesics for “nonmedical” reasons at some time. Yet, on closer inspection, 45% of the “misusers” actually took the drugs for self-medicating physical pain. This was similar to other studies finding that roughly half of so-called “nonmedical use” among students was to relieve pain; albeit, such use was unauthorized due to the person not having a prescription of their own.

As we noted in that earlier UPDATE, an important public health question might be, “Why are so many young persons suffering from untreated (or mistreated) physical pain, causing them to seek remedies on their own?” Perhaps, it is more convenient for them to borrow a few pills from a friend than go to a healthcare provider. Or, are there access-to-care and undertreatment of pain problems among these youngsters that need to be addressed?

It is interesting to observe in the latest SAMHSA data that the group with the highest rates of analgesic misuse are young adults 18-to-25 years old. Surely, this is an active time of life that may be filled with sports injuries and acute physical aches/pains of various types, as well as a period of experimentation with many life experiences — including drugs. Although the data do show some significant declines in drug misuse in this age group, as in the other groups, these young persons might represent a special target for prevention and education efforts.

Meanwhile, in older persons, with the lowest rates of “nonmedical” analgesic use in the SAMHSA data, one might speculate that such misuse more often than not is for the unauthorized self-treatment of pain. Furthermore, the use of marijuana among older age groups could be more often for pain than purely recreational use. We need better ways of capturing and categorizing such data, and then addressing the true underlying problems; although, the government has not shown any interest in doing this in the past. What do readers think?

http://updates.pain-topics.org/2013/01/rx-pain-reliever-misuse-declining.html